Vivos Therapeutics, Inc. (VVOS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 17, 2021, regarding events occurring on June 16, 2021. Vivos Therapeutics, Inc., an emerging growth company incorporated in Delaware, operates in the biotechnology sector. The filing addresses corporate governance matters related to the 2021 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on shareholder meeting logistics and does not contain financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary update is the Board of Directors' approval of the date for the 2021 Annual Meeting of Stockholders, set for July 28, 2021. This date is more than 30 days from the anniversary of the 2020 annual meeting.
Guidance, Outlook, and Corporate Actions
- Annual Meeting Date: Scheduled for July 28, 2021.
- Rule 14a-8 Proposals: The deadline for stockholder proposals to be included in proxy materials is July 2, 2021, by 5:00 p.m. Eastern Time.
- Director Nominations: The deadline for notice of director nominations under the By-Laws was March 20, 2021, by 5:00 p.m. Eastern Standard Time.
- Submission Address: Proposals must be sent to the Corporate Secretary at 9137 South Ridgeline Boulevard, Suite 135, Highlands Ranch, CO 80129.
Key Facts for Investor Verification
- Verify the specific date of the 2021 Annual Meeting (July 28, 2021) against the company's investor relations calendar.
- Confirm the deadline for submitting Rule 14a-8 proposals (July 2, 2021) if intending to submit a shareholder proposal.
- Note that the deadline for director nominations under the By-Laws (March 20, 2021) has already passed for this meeting cycle.
- Review the company's Amended and Restated By-Laws for specific requirements regarding proposal eligibility and director nomination procedures.